A novel approach developed by researchers could reverse liver failure.
As a last resort a liver transplant may be the only remaining option. Junfeng An of the Max Delbruck Centre for Molecular Medicine (MDC) Berlin-Buch and his counterpart Stefan Donath, specialist in internal medicine and cardiology, have developed a new treatment approach based on a mouse model.
The liver failure was reversed and the mice recovered completely. Researchers hope to soon be able to test their new approach in clinical trials with patients, the journal Hepatology reports.
For their treatment approach the two researchers utilised the recently discovered protein ARC (apoptosis repressor with caspase recruitment domain), which serves as the body's own survival switch.
The ARC is pushed in heart and skeletal muscle and in the brain, but not in the liver. In 2006 Donath showed that apoptosis is the cause for the death of myocardial cells (a type of muscle found in heart walls), during a heart failure, but that the infusion of protein ARC stopped them from destruction.
Apoptosis protects the body from diseased or defective cells. In tumour cells apoptosis is deactivated, allowing the cancer cells to proliferate uncontrollably. Cancer researchers are therefore striving to utilise apoptosis to develop a treatment.
However, in acute liver failure the problem is not too little but rather too much apoptosis. Physicians administer drugs in an attempt to halt the destruction of the cells, but only with modest success.
Now Donath and colleagues have tweaked the protein ARC to stop the apoptosis of the liver cells making recovery possible.